Clinical Trials

Urinary Bladder Neoplasms

NCT02516241 2026-04-20

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

1,126 enrolled 52 charts

Urothelial Cancer

NCT05911295 2026-04-20

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

412 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06545955 2026-04-20

ABLE-22

250 enrolled

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

NCT03967977 2026-04-17

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

420 enrolled

Carcinoma, Transitional Cell

NCT04628767 2026-04-17

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Phase 2/3 Recruiting

249 enrolled

Phase 1 Active not recruiting

Renal Pelvis and Ureter Urothelial Carcinoma

NCT00479128 2026-04-16

Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors

80 enrolled

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT07532902 2026-04-16

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

Phase 1 Recruiting

60 enrolled

Carcinoma, Transitional Cell

NCT03317158 2026-04-15

ADAPT-BLADDER

Phase 1/2 Recruiting

55 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03661320 2026-04-15

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

855 enrolled

Urinary Bladder Neoplasms

NCT06524544 2026-04-15

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

320 enrolled

Carcinoma, Transitional Cell

NCT06770582 2026-04-15

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

160 enrolled

Urinary Bladder Neoplasms

NCT07106762 2026-04-15

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

Phase 2/3 Recruiting

470 enrolled

GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms

NCT01352962 2026-04-14

Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors

Phase 1 Completed

18 enrolled

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT03609216 2026-04-13

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

237 enrolled

Infiltrating Bladder Urothelial Carcinoma

NCT03775265 2026-04-13

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

475 enrolled

Urinary Bladder Neoplasms

NCT04164082 2026-04-13

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

161 enrolled

Phase 1 Active not recruiting

Urinary Bladder Neoplasms

NCT04491942 2026-04-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

74 enrolled

BreastGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Triple Negative Breast Neoplasms

NCT04579224 2026-04-13

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

184 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04658862 2026-04-13

SunRISe-2

518 enrolled

Urinary Bladder Neoplasms

NCT06211764 2026-04-13

SunRISe-5

272 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06319820 2026-04-13

MoonRISe-1

641 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06388720 2026-04-13

IMGeS

82 enrolled

Urinary Bladder Neoplasms

NCT07097142 2026-04-08

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

486 enrolled

Urinary Bladder Neoplasms

NCT03093922 2026-04-07

A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

32 enrolled

Carcinoma, Transitional Cell

NCT07000084 2026-04-07

GAIN-BCG

330 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

350 enrolled

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT05538663 2026-04-03

BRIDGE

870 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT05839119 2026-04-02

TASUC-Neo

Phase 1 Terminated

2 enrolled

Urinary Bladder Neoplasms

NCT06704191 2026-03-30

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

Phase 1/2 Recruiting

40 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06960577 2026-03-30

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

150 enrolled

Urinary Bladder Neoplasms

NCT03288545 2026-03-24

EV-103

Phase 1/2 Terminated

348 enrolled 2 FDA

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT02690558 2026-03-20

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

Phase 2 Completed

39 enrolled 16 charts

Urinary Bladder Neoplasms

NCT07129993 2026-03-19

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Phase 2/3 Recruiting

630 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03547973 2026-03-16

TROPHY U-01

827 enrolled 2 FDA

Metastatic Urothelial Cancer

NCT03732677 2026-03-13

NIAGARA

1,063 enrolled 15 charts 2 FDA

Urinary Bladder Neoplasms

NCT06919965 2026-03-13

MoonRISe-3

220 enrolled

Phase 2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT07332351 2026-03-13

TRIFECTA

33 enrolled

Urinary Bladder Neoplasms

NCT06488222 2026-03-11

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

34 enrolled

Urinary Bladder Neoplasms

NCT03036098 2026-03-06

CheckMate901

1,314 enrolled 23 charts 2 FDA

Urothelial Cancer

NCT01104350 2026-03-05

Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy

Phase 1 Completed

19 enrolled

Urinary Bladder Neoplasms

NCT07393542 2026-03-03

A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma

462 enrolled

Carcinoma, Transitional Cell

NCT05644041 2026-02-27

Intravesical Gem/Doce in Patients With NMIBC

25 enrolled

Urinary Bladder Neoplasms

NCT04172675 2026-02-24

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Phase 2 Completed

107 enrolled 17 charts

Phase 3 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07424287 2026-02-20

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

236 enrolled

Phase 2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06972615 2026-02-17

Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy

37 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT04700124 2026-02-05

KEYNOTE-B15

Phase 3 Completed

808 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT03682068 2026-02-03

NILE

1,246 enrolled